Empagliflozin to Prevent Progressive Adverse Remodelling After Myocardial Infarction (EMPRESS-MI): Rationale and Design
ESC Heart Failure · 2024
DOI: 10.1002/ehf2.14830 ↗At a glance
Journal article in ESC Heart Failure, 2024. Written by Jaclyn Carberry and 20 co-authors. Institution: British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. Major MEDLINE topics: Benzhydryl Compounds, Glucosides, Magnetic Resonance Imaging, Cine, Myocardial Infarction. Cited 10 times so far (Crossref); 57 references. The full text is freely available (open access, CC BY 4.0). Funded by: Boehringer Ingelheim, British Heart Foundation Centre of Research Excellence Grant.
Abstract (original language)
Aims
Patients with a reduced left ventricular ejection fraction (LVEF) following an acute myocardial infarction (MI) are at risk of progressive adverse cardiac remodelling that can lead to the development of heart failure and death. The early addition of a sodium-glucose cotransporter 2 (SGLT2) inhibitor to standard treatment may delay or prevent progressive adverse remodelling in these patients. Methods and results EMpagliflozin to PREvent worSening of left ventricular volumes and Systolic function after Myocardial Infarction (EMPRESS-MI) is a randomized, double-blind, placebo-controlled, multi-centre trial designed to assess the effect of empagliflozin on cardiac remodelling evaluated using cardiovascular magnetic resonance (CMR) in 100 patients with left ventricular systolic dysfunction following MI. Eligible patients were those ≥12 h and ≤14 days following acute MI, with an LVEF <45% by CMR. Patients were randomized to empagliflozin 10 mg once a day or matching placebo. The primary outcome will be change in left ventricular end-systolic volume indexed to body surface area over 24 weeks from randomization. Secondary endpoints include measures of left ventricular and atrial volumes, left ventricular mass, LVEF, and circulating cardiac biomarkers.
Conclusions
EMPRESS-MI will assess the effect of the SGLT2 inhibitor empagliflozin on cardiac remodelling in patients with left ventricular systolic dysfunction after an acute MI.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
- Golden Jubilee National Hospital, Clydebank, UK.
- West of Scotland Innovation Hub, National Health Service, Glasgow, UK.
- National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
- Robertson Centre for Biostatistics, School of Health and Wellbeing, University of Glasgow, Glasgow, UK.
ORCID profiles: Kieran F Docherty
Funding
- Boehringer Ingelheim
- British Heart Foundation Centre of Research Excellence Grant
Cite
APA
Carberry, J., Petrie, M. C., Lee, M. M. Y., Brooksbank, K., Campbell, R. T., Good, R., Jhund, P. S., Kellman, P., Lang, N. N., Mangion, K., Mark, P. B., McConnachie, A., McMurray, J. J. V., Meyer, B., Orchard, V., Shaukat, A., Watkins, S., Welsh, P., Sattar, N., …, & Docherty, K. F. (2024). Empagliflozin to Prevent Progressive Adverse Remodelling After Myocardial Infarction (EMPRESS-MI): Rationale and Design. ESC Heart Failure. https://doi.org/10.1002/ehf2.14830
Vancouver
Carberry J, Petrie MC, Lee MMY, Brooksbank K, Campbell RT, Good R, et al. Empagliflozin to Prevent Progressive Adverse Remodelling After Myocardial Infarction (EMPRESS-MI): Rationale and Design. ESC Heart Failure. 2024. doi:10.1002/ehf2.14830
BibTeX
@article{Carberry2024,
author = {Carberry, Jaclyn and Petrie, Mark C and Lee, Matthew M Y and Brooksbank, Katriona and Campbell, Ross T and Good, Richard and Jhund, Pardeep S and Kellman, Peter and Lang, Ninian N and Mangion, Kenneth and Mark, Patrick B and McConnachie, Alex and McMurray, John J V and Meyer, Barbara and Orchard, Vanessa and Shaukat, Aadil and Watkins, Stuart and Welsh, Paul and Sattar, Naveed and Berry, Colin and Docherty, Kieran F},
title = {Empagliflozin to Prevent Progressive Adverse Remodelling After Myocardial Infarction (EMPRESS-MI): Rationale and Design},
journal = {ESC Heart Failure},
year = {2024},
doi = {10.1002/ehf2.14830}
}
EUVIMED